Protein Profiling Platform - Quality Assurance

High quality standards are essential for robust and reliable Biomarker Discovery and Verification as well as for the discovery of new Drug Targets. During the last 10 years a stringent quality assurance workflow has been established for our Antibody Array Platform in order to conduct immuno-based biomedical discovery studies with excellent standards in terms of reproducibility and platform stability. The automated assay workflow further improves the performance of our service. 

 

Biomarker Discovery Phase - scioDiscover Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • Targets identified through transcriptional studies and expert input
  • Stringent QC management
  • Features:  
    • cross-species activity (human and mouse for high versatility)
    • detection of several protein isoforms
    • cost-efficiency through high content

  

Verification Phase - Custom Array Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • In-house QC on Western Blot (different cell lines or tissues) and optional ELISA-based tests
  • In-house QC on large-scale protein arrays (> 9.000 human proteins)
  • In-depth validation of array performance
  • Definition of biomarker signature with highest accuracy
  • Selection of appropriate binders / sandwich pairs
  • Features:  
    • specifically designed antibodies for further use in diagnostic assays
    • fully renewable antibody formats
    • in-depth quality controlled (WB, ELISA)
    • comprehensive cross-reactivity profile (large-scale protein arrays)

 

Orthogonal Biomarker Validation

Verified Candidates can be further validated by orthogonal methods according to customer’s requirements

  • Western Blotting ( WB )
  • ELISA
  • Immuno-Precipitation ( IP )
  • Mass spectrometry ( MS )
  • Biacore

 

Overview
Scio-Discover
    Biomarker
Discovery
    Custom Microarrays
for Biomarker Verification
    Contact
us

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 202212, 852.
New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).
New article | Biomarker identification and verification in endometriosis

| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

biomarkers in endometriosis

 

New article | Parkinson's Disease analysed via brain organoids

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 13 days ago

    RT @REPO4EU: NEWS❗📣 Our Website is now LIVE❗ OPEN CALL to #Abstracts! #REPO4EU kicks-off with a 💊1st Int'l #Conference on #DrugRepurposing

  • 57 days ago

    Partner with us at #BIO2022 International Convention in San Diego CA and learn about our smart protein biomarker po… https://t.co/kYObhmyG1B

  • 58 days ago

    RT @Fusion_Conf: Final day of the 3rd Cell Death, Cell Stress & Metabolism Conference. We are looking forward to more outstanding talks thi…

  • 58 days ago

    We are here for the 3rd and final day of the 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22, at Cancu… https://t.co/g8MUcdyEkm

  • 61 days ago

    En-route to attending 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22 Dr Anne Griesbeck will be giving… https://t.co/JrXTQGQoj3